Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement
- PMID: 32240433
- DOI: 10.1007/s10067-020-05050-2
Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement
Abstract
Background: Psoriatic arthritis (PsA) patients are often affected by numerous comorbidities. However, contrasting results have been reported with regard to the respiratory involvement in PsA patients. The aim of this study was to evaluate the presence of subclinical airway inflammation in non-smoking PsA patients compared to patients with only psoriasis using the fraction of exhaled nitric oxide (FeNO) as an indirect marker of airway inflammation.
Methods: The study included 164 non-smoking psoriatic patients (Psoriasis Area of Severity Index or PASI score > 10): 82 with and 82 without PsA, who underwent FeNO tests at different flow rates (30, 50, 100, 200 mL/s). PsA patients were evaluated with Disease Activity in PSoriatic Arthritis Score (DAPSA). Both study groups were compared in terms of FeNO values and its association with the PASI score. The correlations between the variables were evaluated by means of Pearson's coefficient.
Results: Patient with PsA had higher levels of FeNO than those with psoriasis but without arthritis (at 30 mL/s, 71.09 ± 18.40 ppb vs 66.88 ± 19.12 ppb (NS); at 50 mL/s, 36.61 ± 9.30 ppb vs 30.88 ± 9.73 ppb (p < 0.001); at 100 mL/s, 19.09 ± 4.66 ppb vs 16.63 ± 4.90 ppb (p < 0.001); and at 200 mL/s, 10.88 ± 2.53 ppb vs 9.43 ± 2.55 ppb (p < 0.001), respectively). PASI score correlated to FeNO only in psoriatic patients without arthritis. However, CASPAR index correlated with FeNO (FeNO30: r = 0.81, p < 0.001; FeNO50: r = 0.84, p < 0.001; FeNO100: r = 0.71, p < 0.001; FeNO200: r = 0.58, p < 0.001). DAPSA was also correlated with FeNO to all flows (FeNO30: r = 0.43, p < 0.001; FeNO50: r = 0.33, p < 0.001; FeNO100: r = 0.34, p < 0.001; FeNO200: r = 0.25, p < 0.001).
Conclusions: PsA patients seem to have more commonly subclinical airway inflammation than those with only psoriasis. Further studies are needed to replicate these findings. Key Points • Fraction of exhaled nitric oxide (FeNO) is a useful device to detect and monitor airway inflammation not only in asthma but also in systemic inflammatory diseases such as psoriatic arthritis and psoriasis. • Clinicians should be aware to check respiratory diseases in patients with psoriatic arthritis.
Keywords: Airway inflammation; CASPAR; FeNO; PASI; Psoriasis; Psoriatic arthritis.
Similar articles
-
A comparative study on the value of lower airway exhaled nitric oxide combined with small airway parameters for diagnosing cough-variant asthma.Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231181259. doi: 10.1177/17534666231181259. Ther Adv Respir Dis. 2023. PMID: 37326344 Free PMC article.
-
Fatigue in psoriatic arthritis: Is it related to disease activity?Int J Rheum Dis. 2021 Mar;24(3):418-425. doi: 10.1111/1756-185X.14069. Epub 2021 Jan 27. Int J Rheum Dis. 2021. PMID: 33506651
-
Differences in oxylipin profile in psoriasis versus psoriatic arthritis.Arthritis Res Ther. 2021 Jul 24;23(1):200. doi: 10.1186/s13075-021-02575-y. Arthritis Res Ther. 2021. PMID: 34303373 Free PMC article.
-
Psoriasis and Respiratory Comorbidities: The Added Value of Fraction of Exhaled Nitric Oxide as a New Method to Detect, Evaluate, and Monitor Psoriatic Systemic Involvement and Therapeutic Efficacy.Biomed Res Int. 2018 Sep 23;2018:3140682. doi: 10.1155/2018/3140682. eCollection 2018. Biomed Res Int. 2018. PMID: 30345297 Free PMC article. Review.
-
Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.J Autoimmun. 2017 Jan;76:21-37. doi: 10.1016/j.jaut.2016.10.009. Epub 2016 Nov 9. J Autoimmun. 2017. PMID: 27836567 Review.
Cited by
-
Role of Fetuin-A in the Pathogenesis of Psoriasis and Its Potential Clinical Applications.Clin Cosmet Investig Dermatol. 2022 Apr 8;15:595-607. doi: 10.2147/CCID.S356801. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 35422648 Free PMC article. Review.
-
Exhaled nitric oxide in early rheumatoid arthritis and effects of methotrexate treatment.Sci Rep. 2022 Apr 20;12(1):6489. doi: 10.1038/s41598-022-10334-5. Sci Rep. 2022. PMID: 35444250 Free PMC article.
-
Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database.Open Access Rheumatol. 2022 Jun 15;14:123-132. doi: 10.2147/OARRR.S342123. eCollection 2022. Open Access Rheumatol. 2022. PMID: 35734243 Free PMC article.
-
Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study.Dermatol Ther (Heidelb). 2025 Feb;15(2):427-436. doi: 10.1007/s13555-025-01338-w. Epub 2025 Jan 24. Dermatol Ther (Heidelb). 2025. PMID: 39849247 Free PMC article.
-
Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study.Dermatol Ther (Heidelb). 2023 Oct;13(10):2229-2246. doi: 10.1007/s13555-023-00987-z. Epub 2023 Aug 12. Dermatol Ther (Heidelb). 2023. PMID: 37573289 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous